3SBio Acquires Control of CP Guojian in $213 Million Deal

3SBio of Shenyang expanded its biosimilar business by raising its stake in Shanghai CP Guojian Pharma to 54%. 3SBio, which acquired 7% of Guojian last year, paid $213 million for 47% of Guojian's outstanding shares. Guojian has two biosimilar products on the market: Yisaipu, a biosimilar to Amgen's Enbrel anti-inflammatory drug, and Xenopax, a biosimilar to Biogen's Zinbryta anti-organ rejection treatment. In addition, Guojian has a portfolio of mAbs awaiting CFDA approval and a mAb manufacturing facility. More details.... Stock Symbols: (HK: 1530) (NSDQ: AMGN) (NSDQ: BIIB) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.